The Indian Council of Medical Research-led COVID-19 National Task Force has dropped the use of the drugs Ivermectin and Hydroxychloroquine (HCQ) from the revised “clinical guidance for management of adult COVID-19 patients”.

The All India Institute of Medical Sciences (AIIMS) and the Indian Council of Medical Research (ICMR) national task force for COVID-19 and the Joint Monitoring Group made the recommendation following a meeting on August 20. The previous clinical guidance was issued on May 19.

“HCQ may be considered for removal from guideline, with recommendation to use with caution only in clinical trial setting (since there is some genuine uncertainty regarding the possible benefit for severe cases and in low dose). Many studies showing increased mortality risk (10/13) and low mortality benefit of HCQ(2/13). Considering evidence for increased ADE(6/13) , especially with Azithromycin and only one study showed no increase in ADE(1/13),” said the revised guidelines for COVID management.

https://www.thehindu.com/news/national/ivermectin-and-hcq-drugs-dropped-from-revised-clinical-guidance-for-management-of-adult-covid-19-patients/article36651890.ece?homepage=true